Study of immune, muscle, and genetic features in LGMD 2B
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This study looks at immune function, muscle appearance, and genetic information in people with limb-girdle muscular dystrophy type 2B. It may help researchers understand the condition better, which can support future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old (inclusive)
- You have a confirmed genetic diagnosis of limb-girdle muscular dystrophy type 2B (LGMD 2B)
- You agree to take part by signing the informed consent form
- You are not part of the study team (investigator, coordinator, or other staff linked to the study)
- You have not had a life-threatening or organ-related emergency in the last 6 months (such as heart, kidney, liver problems, heart attack, stroke, or serious infection)
- Your alcohol use is not more than 20 grams per day
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how specific gene changes relate to the pattern of muscle weakness in people with limb-girdle muscular dystrophy (LGMD). It may help doctors better understand the condition and improve future care.
This study tracks changes in muscle strength and breathing over time in people with certain types of muscular dystrophy. It helps researchers develop better tests to measure how the disease progresses.
This study follows people with LAMA2-related muscular dystrophy over time to better understand the condition. It may help with future treatments by learning more about how the disease progresses.
This study looks at a new protein that might help people with LAMA2-related muscular dystrophy. It uses stored samples to see if the protein could be a useful addition to future treatments.
This study follows people with LAMA2-related muscular dystrophy (a genetic muscle-weakening condition) to learn how it changes over time and find better ways to measure it. By participating, you help researchers identify new disease markers that could improve future treatments.
This study collects blood and, for some people, muscle tissue to look for signs (biomarkers) that can help track and better understand myotonic dystrophy. You may help by providing samples and basic muscle function testing, depending on your age and condition type.
Hear when a new Dysferlinopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.